Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
47.65 CHF | -0.83% | -3.35% | +11.46% |
Feb. 16 | BB Biotech's Loss Narrows in FY23; Operating Income Down | MT |
Feb. 14 | BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 32.1M 36.16M | Sales 2025 * | 100M 113M | Capitalization | 2.61B 2.94B |
---|---|---|---|---|---|
Net income 2024 * | 25M 28.16M | Net income 2025 * | 72M 81.1M | EV / Sales 2024 * | 92.4 x |
Net Debt 2024 * | 354M 398M | Net Debt 2025 * | 362M 408M | EV / Sales 2025 * | 29.7 x |
P/E ratio 2024 * |
95.3
x | P/E ratio 2025 * |
16
x | Employees | 10 |
Yield 2024 * |
5.16% | Yield 2025 * |
5.16% | Free-Float | 97.24% |
1 day | -0.83% | ||
1 week | -1.45% | ||
Current month | +4.04% | ||
1 month | -2.85% | ||
3 months | +14.27% | ||
6 months | +8.91% | ||
Current year | +11.46% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Koller
CIO | Chief Investment Officer | 54 | 03-12-31 |
- | - | ||
- | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Erich Hunziker
CHM | Chairman | 70 | 11-03-20 |
Clive Meanwell
BRD | Director/Board Member | 67 | 03-12-31 |
Director/Board Member | 63 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 47.65 | -0.83% | 76,770 |
24-03-15 | 48.05 | +1.48% | 97,673 |
24-03-14 | 47.35 | -0.73% | 77,700 |
24-03-13 | 47.7 | -2.55% | 87,927 |
24-03-12 | 48.95 | -0.71% | 61,785 |
Delayed Quote Swiss Exchange, March 18, 2024 at 12:31 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+11.46% | 2.98B | |
+9.72% | 46B | |
+35.14% | 39.85B | |
+4.84% | 39.76B | |
-9.43% | 28.16B | |
+17.47% | 27.62B | |
-22.99% | 18.8B | |
+10.88% | 13.3B | |
+27.53% | 12.2B | |
-6.84% | 11.4B |